Floatz logo

19 assets in Estrogen-Receptor Negative Breast Cancer

Therapeutic assets addressing Estrogen-Receptor Negative Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Estrogen-Receptor Negative Breast Cancer
Northwestern UniversityP3BBB (72)
Cis-Diamminedichloroplatinum Ii
Estrogen-Receptor Negative Breast Cancer
University of WashingtonP3BB (71)
Epirubicin
Estrogen-Receptor Negative Breast Cancer
Massachusetts General HospitalP2BB (71)
Pembrolizumab
Estrogen-Receptor Negative Breast Cancer
Massachusetts General HospitalP2BB (71)
Cyclophosphamide
Estrogen-Receptor Negative Breast Cancer
Massachusetts General HospitalP3BB (70)
Adriamycin
Estrogen-Receptor Negative Breast Cancer
Roswell Park Cancer InstituteP3BB (68)
Capecitabine
Estrogen-Receptor Negative Breast Cancer
Kristina A. FanucciP3BB (68)
Trastuzumab
Estrogen-Receptor Negative Breast Cancer
Jules Bordet InstituteP2B (62)
Datopotamab Deruxtecan
Estrogen-Receptor Negative Breast Cancer
Sarah Sammons, MDP2CCC (53)
Decitabine
Estrogen-Receptor Negative Breast Cancer
Virginia Commonwealth UniversityP2CCC (53)
Elacestrant
Estrogen-Receptor Negative Breast Cancer
Kristina A. FanucciP2CCC (53)
Panitumumab
Estrogen-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterP2CCC (53)
Pertuzumab
Estrogen-Receptor Negative Breast Cancer
Jules Bordet InstituteP2CCC (53)
Trastuzumab Emtansine
Estrogen-Receptor Negative Breast Cancer
Jules Bordet InstituteP2CCC (53)
Olaparib
Estrogen-Receptor Negative Breast Cancer
OHSU Knight Cancer InstituteP1CC (47)
Capivasertib
Estrogen-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterP1CC (43)
Modified Vaccinia Virus Ankara Vaccine Expressing P53
Estrogen-Receptor Negative Breast Cancer
City of Hope Medical CenterP1CC (43)
Vistusertib
Estrogen-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterP1CC (43)
Technetium Tc 99M Sestamibi
Estrogen-Receptor Negative Breast Cancer
M.D. Anderson Cancer CenterEarly P1C (39)